LS9

Building Better Biofuels:Startup LS9 is developing microbes that produce hydrocarbons

Building Better Biofuels:Startup LS9 is developing microbes that produce hydrocarbons

June 6, 2007

Wednesday, June 06, By Neil Savage

The U.S. Department of Energy has set a goal of replacing 30 percent of gasoline used in the United States with fuels from renewable biological sources by 2030, and President Bush has made ethanol production a priority. So it is hardly surprising that some biotech startup companies are positioning themselves to take advantage of an anticipated booming market for biofuels.

LS9

Renewable Petroleum Company LS9 Announces Distinguished Hire

Renewable Petroleum Company LS9 Announces Distinguished Hire

June 18, 2007

SAN CARLOS, Calif., June 18 /PRNewswire/ -- LS9, the Renewable Petroleum Company (TM), today announced that it has named Dr. Fernando Valle as its Senior Director of Metabolic Engineering, a key position in its effort to commercially deliver a clean, renewable petroleum substitute. LS9 will offer a broad portfolio of DesignerBiofuels (TM) products that are lab-engineered for various commercial end-uses, including custom, fit-for-purpose gasoline, diesel, and jet fuel formulations.

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals CEO Tuan Ha-Ngoc Receives Ernst & Young New England Entrepreneur Of The Year® Award

AVEO Pharmaceuticals CEO Tuan Ha-Ngoc Receives Ernst & Young New England Entrepreneur Of The Year® Award

June 18, 2007

CAMBRIDGE, MA, June 18, 2007 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that its president and chief executive officer, Tuan Ha-Ngoc, has been awarded the Ernst & Young New England Entrepreneur of the Year® in the life sciences category.

Helicos BioSciences Corporation

Helicos BioSciences Strengthens Executive Management Team in Preparation for Commercial Launch

Helicos BioSciences Strengthens Executive Management Team in Preparation for Commercial Launch

June 19, 2007

 CAMBRIDGE, Mass., Jun 19, 2007 (BUSINESS WIRE) -- Helicos BioSciences Corporation (NASDAQ: HLCS) announced today the addition of new members to its executive management team as a key step in building a commercial organization. Chip Leveille has been appointed Vice President of Sales and Marketing and Mark Solakian has been named Vice President and General Counsel.

Color Kinetics

Color Kinetics Announces Acquisition by Philips

Color Kinetics Announces Acquisition by Philips

June 19, 2007

Intelligent LED lighting pioneer joins global lighting leader

Mascoma Corporation

Mascoma Corporation Names James Flatt Senior Vice President of Research and Development

Mascoma Corporation Names James Flatt Senior Vice President of Research and Development

June 20, 2007

To Apply Fermentation Research and Strain Development Expertise

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mascoma Corporation, a leader in low-carbon cellulosic biomass-to-ethanol development and production, today named James H. Flatt, Ph.D. as Senior Vice President, Research and Development. In this position, Dr. Flatt will lead the company’s initiatives to develop environmentally beneficial and cost-effective technologies to convert cellulosic biomass into ethanol.

Helicos BioSciences Corporation

Helicos BioSciences Announces Commencement of Commercial Manufacturing

Helicos BioSciences Announces Commencement of Commercial Manufacturing

June 25, 2007

Industry Expert, William Cotter, Joins Helicos as Vice President of Operations

Epitome Biosystems

Epitome Biosystems Initiates Second Partnership with EMD Chemicals for Commercial Products

Epitome Biosystems Initiates Second Partnership with EMD Chemicals for Commercial Products

July 10, 2007

Waltham, MA, July 10, 2007 – Epitome Biosystems announced today a second licensing and development agreement with EMD Chemicals Inc., an affiliate of Merck KGaA of Germany, using Epitome’s EpiTag™ technology. The partnership will focus on developing EpiTag™ assays for the quantitative measurement of various targets, including membrane proteins. Products will be manufactured, marketed and sold worldwide for research applications by EMD through its well-known Novagen® brand. Sample analysis will be available as a service from Epitome.

Adnexus Therapeutics

Adnexus Therapeutics Appoints Martin Freed, MD as Chief Medical Officer

Adnexus Therapeutics Appoints Martin Freed, MD as Chief Medical Officer

July 11, 2007

Waltham, MA, July 11, 2007 – Adnexus Therapeutics today announced the expansion of its management team with the appointment of Martin I. Freed, M.D., F.A.C.P. to the newly-created role of Chief Medical Officer. Dr. Freed is an experienced drug developer in several therapeutic areas. He played a key role in the development of Avandia® (rosiglitazone maleate), a drug to treat metabolic disease, including guiding its development from a preclinical compound to the market place, and he also has experience in oncology and inflammation drug development.

Ze-gen, Inc.

Ze-gen, Inc. Secures $4.5 Million in Series A Funding from Flagship Ventures and VantagePoint Venture Partners

Ze-gen, Inc. Secures $4.5 Million in Series A Funding from Flagship Ventures and VantagePoint Venture Partners

July 16, 2007

Adds Seasoned CleanTech Investors to Board of Directors